Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
Abstract In the field of oncology research, a deeper understanding of tumor biology has shed light on the role of environmental conditions surrounding cancer cells. In this regard, targeting the tumor microenvironment has recently emerged as a new way to access this disease. In this work, a novel extracellular matrix (ECM)-targeting nanotherapeutic was engineered using a lipid-based nanoparticle chemically linked to an inhibitor of the ECM-related enzyme, lysyl oxidase 1 (LOX), that inhibits the crosslinking of elastin and collagen fibers. We demonstrated that, when the conjugated vesicles were loaded with the chemotherapeutic epirubicin, superior inhibition of triple negative breast cancer (TNBC) cell growth was observed both in vitro and in vivo. Moreover, in vivo results displayed prolonged survival, minimal cytotoxicity, and enhanced biocompatibility compared to free epirubicin and epirubicin-loaded nanoparticles. This all-in-one nano-based ECM-targeting chemotherapeutic may provide a key-enabling technology for the treatment of TNBC..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Scientific Reports - 11(2021), 1, Seite 12 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Alessandro De Vita [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
---|
doi: |
10.1038/s41598-021-84492-3 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ061871117 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ061871117 | ||
003 | DE-627 | ||
005 | 20230309014212.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41598-021-84492-3 |2 doi | |
035 | |a (DE-627)DOAJ061871117 | ||
035 | |a (DE-599)DOAJf3592b74807643ad8fc46e879476242d | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a Alessandro De Vita |e verfasserin |4 aut | |
245 | 1 | 0 | |a Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract In the field of oncology research, a deeper understanding of tumor biology has shed light on the role of environmental conditions surrounding cancer cells. In this regard, targeting the tumor microenvironment has recently emerged as a new way to access this disease. In this work, a novel extracellular matrix (ECM)-targeting nanotherapeutic was engineered using a lipid-based nanoparticle chemically linked to an inhibitor of the ECM-related enzyme, lysyl oxidase 1 (LOX), that inhibits the crosslinking of elastin and collagen fibers. We demonstrated that, when the conjugated vesicles were loaded with the chemotherapeutic epirubicin, superior inhibition of triple negative breast cancer (TNBC) cell growth was observed both in vitro and in vivo. Moreover, in vivo results displayed prolonged survival, minimal cytotoxicity, and enhanced biocompatibility compared to free epirubicin and epirubicin-loaded nanoparticles. This all-in-one nano-based ECM-targeting chemotherapeutic may provide a key-enabling technology for the treatment of TNBC. | ||
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
653 | 0 | |a Science | |
653 | 0 | |a Q | |
700 | 0 | |a Chiara Liverani |e verfasserin |4 aut | |
700 | 0 | |a Roberto Molinaro |e verfasserin |4 aut | |
700 | 0 | |a Jonathan O. Martinez |e verfasserin |4 aut | |
700 | 0 | |a Kelly A. Hartman |e verfasserin |4 aut | |
700 | 0 | |a Chiara Spadazzi |e verfasserin |4 aut | |
700 | 0 | |a Giacomo Miserocchi |e verfasserin |4 aut | |
700 | 0 | |a Francesca Taraballi |e verfasserin |4 aut | |
700 | 0 | |a Michael Evangelopoulos |e verfasserin |4 aut | |
700 | 0 | |a Federica Pieri |e verfasserin |4 aut | |
700 | 0 | |a Alberto Bongiovanni |e verfasserin |4 aut | |
700 | 0 | |a Laura Mercatali |e verfasserin |4 aut | |
700 | 0 | |a Ennio Tasciotti |e verfasserin |4 aut | |
700 | 0 | |a Toni Ibrahim |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Scientific Reports |d Nature Portfolio, 2011 |g 11(2021), 1, Seite 12 |w (DE-627)DOAJ000049077 |x 20452322 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g pages:12 |
856 | 4 | 0 | |u https://doi.org/10.1038/s41598-021-84492-3 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/f3592b74807643ad8fc46e879476242d |z kostenfrei |
856 | 4 | 0 | |u https://doi.org/10.1038/s41598-021-84492-3 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2045-2322 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 11 |j 2021 |e 1 |h 12 |